Speech in Hepatic Encephalopathy (HE)

Status Active, not recruiting

Clinical Trial Summary

This is an observational study that will test the clinical significance of speech features in patients with cirrhosis. It aims to assess if speech is associated with cognitive function at baseline, if speech predicts changes in cognition, and if speech predicts future events of hepatic encephalopathy (cirrhosis-related confusion), as well as to assess the dynamics of speech over time, especially with episodes of overt hepatic encephalopathy (OHE) and treatment interventions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05425316
Study type	Observational
Source	University of Michigan
Contact
Status	Active, not recruiting
Phase
Start date	October 5, 2021
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01559519` - Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy	Phase 4
Terminated	`NCT01846806` - The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.	N/A
Recruiting	`NCT01178372` - Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis	Phase 4
Completed	`NCT00914056` - A Study of Controlled Lactulose Withdrawal	N/A
Completed	`NCT00740142` - Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy	Phase 4
Completed	`NCT00558038` - Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy	Phase 2
Completed	`NCT00986895` - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group	Phase 1
Completed	`NCT00287235` - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)	N/A
Recruiting	`NCT05539027` - Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy	Phase 4
Recruiting	`NCT04096014` - Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy	N/A
Completed	`NCT05526404` - Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration	N/A
Completed	`NCT04082780` - Rifamycin in Minimal Hepatic Encephalopathy	Phase 2
Enrolling by invitation	`NCT06367127` - Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
Recruiting	`NCT04415294` - Flicker App for Minimal Hepatic Encephalopathy
Not yet recruiting	`NCT06072521` - Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy	Phase 2
Completed	`NCT02636647` - Fecal Transplant in Recurrent Hepatic Encephalopathy	Phase 1
Withdrawn	`NCT02086825` - A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure	Phase 3
Completed	`NCT01446523` - S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE	N/A
Completed	`NCT01218568` - Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial	N/A
Completed	`NCT01008293` - Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life	Phase 2/Phase 3